)

Lytix Biopharma (LYTIX) investor relations material
Lytix Biopharma Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
Advancing toward commercialization with a robust clinical pipeline, including Ruxotemitide (LTX-315) moving toward Phase III in basal cell carcinoma and ongoing Phase II in melanoma, supported by a partnership with Verrica Pharmaceuticals.
Completed patient treatment in late-stage melanoma trial (ATLAS-IT-05), showing 40% disease control in a challenging population.
Significant reduction in Q2 2025 net loss, driven by a NOK 10.2 million accrual reversal related to ATLAS-IT-05.
Cash and short-term investments of NOK 100–100.3 million as of June 30, 2025, provide operational runway into 2026.
Strengthened board and management to support late-stage execution and commercialization.
Financial highlights
Q2 2025 net loss substantially reduced due to a NOK 10.2 million one-off accrual reversal and lower R&D activity.
Cash and short-term investments at period end totaled NOK 100–100.3 million.
Total liabilities decreased from NOK 38.6 million at year-end 2024 to NOK 20–20.1 million at June 2025.
Loss from operations for H1 2025 was NOK 18.6 million, improved from NOK 40.2 million in H1 2024.
Equity ratio improved to 81.7% as of June 30, 2025.
Outlook and guidance
Interim data from the NeoLIPA melanoma study expected in November 2025; top-line results in H1 2026.
Preparations for pivotal Phase III BCC trial ongoing, with milestone payment expected upon study start, likely in H1 2026.
LTX-401 preclinical program advancing toward clinical development.
Additional genomic and immune response data from Verrica’s Phase II BCC study to be presented later in 2025.
Continued focus on cost control and flexibility for key catalysts in H2 2025.
Next Lytix Biopharma earnings date

Next Lytix Biopharma earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage